DOCSLIB.ORG

Investigating the Therapeutic Potential of NUAK1 for the Treatment of Colorectal Cancer. Phd Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigating the Therapeutic Potential of NUAK1 for the Treatment of Colorectal Cancer. Phd Thesis Port, Jennifer Lynne Forbes (2018) Investigating the therapeutic potential of NUAK1 for the treatment of colorectal cancer. PhD thesis. https://theses.gla.ac.uk/9125/ Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] Investigating the Therapeutic Potential of NUAK1 for the Treatment of Colorectal Cancer Jennifer Lynne Forbes Port This thesis is submitted to the University of Glasgow in fulfilment of the requirements of the Degree of Doctor of Philosophy. Institute of Cancer Sciences College of Medical, Veterinary, and Life Sciences University of Glasgow The Beatson Institute for Cancer Research Garscube Estate Glasgow September 2017 Abstract NUAK1 (aka ARK5) is a member of the AMPK-related kinase family and has been associated with many essential cellular processes that are often perturbed in cancer. Elevated NUAK1 expression has been observed in advanced stages of colorectal cancer (CRC) and is further enriched in liver metastasis in human patients. Therefore, NUAK1 is a novel tumour progression-associated factor, however, its primary function in this context and its use as a potential therapeutic target remains unclear. NUAK1 was previously identified as synthetic lethal in MYC-overexpressing tumour cells. This study shows that high NUAK1 levels correspond to poor patient survival in human CRC, and that increased NUAK1 RNA correlates with advanced tumour stages in a human TMA of CRC. Using mouse models of CRC, it is demonstrated that Nuak1 deletion inhibits colon tumour initiation, and acute depletion of Nuak1 by shRNA in established tumours significantly reduces tumour burden after just 7 days of shRNA activation. Interrogation of tumours acutely depleted of Nuak1 showed decreased cell proliferation concurrent with increased ROS and cell death. Interestingly, the requirement for Nuak1 did not extend to healthy wildtype intestine; depletion of Nuak1 in mouse intestine had no impact on cell death, proliferation or differentiation, and wildtype 3D organoids were resistant to Nuak1 inhibition. Using human CRC cell lines and transformed 3D organoid cultures, the study confirms that the NRF2 oxidative stress response is compromised in NUAK1 depleted cells, and treatment with a ROS scavenger can rescue the detrimental consequences of this in vitro, ex vivo and in vivo. Mechanistically, it was found that NUAK1 is necessary for the nuclear accumulation of NRF2 by counteracting negative regulation of this process by GSK3β, and that direct inhibition of GSK3β is able to restore NRF2 nuclear accumulation in NUAK1 deficient cells. Furthermore, it is shown that ROS-dependent activation of NUAK1 by cysteine oxidisation leads to the phosphorylation of MYPT1. Activation of MYPT1 results in the suppression of PP1β activity, which in turn inhibits dephosphorylation of GSK3β thus allowing NRF2 to accumulate in the nucleus and upregulate the anti-oxidant response pathway. In summary, this thesis is proposing a fascinating, new and conserved mechanism of redox signal transduction in which activation of NUAK1 coordinates PP1βMYPT1 inhibition, with AKT activation in order to suppress GSK3β-dependent inhibition of 2 NRF2 nuclear import. Exploiting the heightened sensitivity of tumour cells to ROS is emerging as a plausible strategy for cancer therapy and is implicated in the resistance to chemotherapy. Therefore, inhibiting the anti-oxidant response via transient inhibition of NUAK1 may offer a new strategy for improving therapeutic outcomes in cancer. 3 Table of Contents List of Tables ........................................................................................................................ 7 List of Figures ....................................................................................................................... 8 Acknowledgements ............................................................................................................. 10 Abbreviations ..................................................................................................................... 13 Chapter 1 Introduction ...................................................................................................... 18 1.1 Colorectal Cancer ................................................................................................................. 18 1.2 CRC clinical manifestations................................................................................................. 18 1.3 Clinical diagnosis and staging.............................................................................................. 18 1.3.1 TNM Classification of Malignant Tumours (TNM) .............................................................. 19 1.3.2 The Dukes’ staging system ............................................................................................................ 22 1.4 Current treatment of CRC .................................................................................................. 22 1.5 Normal Intestinal Homeostasis ............................................................................................ 23 1.6 Molecular characterization of CRC .................................................................................... 25 1.6.1 Adenomatous polyposis coli (APC), β-Catenin and Wnt signalling .............................. 26 1.6.2 MYC deregulation in CRC ............................................................................................................... 27 1.6.3 The ‘adenoma-to-carcinoma’ sequence ................................................................................... 28 1.6.4 KRAS ....................................................................................................................................................... 31 1.6.5 Other common mutations in CRC ............................................................................................... 33 1.6.6 The consensus molecular subtypes of CRC ............................................................................ 34 1.7 Approaches to modelling CRC ............................................................................................ 35 1.7.1 Human cell lines ................................................................................................................................ 35 1.7.2 Intestinal organoids ......................................................................................................................... 36 1.7.3 Genetically engineered mouse models (GEMMs) ................................................................ 37 1.8 AMPK-Related kinases ........................................................................................................ 43 1.8.1 AMPK ...................................................................................................................................................... 43 1.8.2 AMPK-related kinases ..................................................................................................................... 44 1.8.3 NUAK1 and NUAK2: structure, expression and a common target ................................ 46 1.8.4 NUAK2: function and regulation................................................................................................. 49 1.9 NUAK1 .................................................................................................................................. 50 1.9.1 NUAK1: function and regulation................................................................................................. 50 1.9.2 NUAK1 mouse models .................................................................................................................... 51 1.9.3 NUAK1 and cancer ............................................................................................................................ 52 1.9.4 NUAK1 and synthetic lethality .................................................................................................... 54 1.10 Aims of the project ............................................................................................................. 58 Chapter 2 Materials & Methods ....................................................................................... 60 2.1 Mouse experiments and analyses ........................................................................................ 60 2.1.1 Colony Maintenance ........................................................................................................................ 60 2.1.2 Genotyping ........................................................................................................................................... 60 2.1.3 Experimental Cohorts ..................................................................................................................... 60 2.1.4 Tissue preparation and scoring .................................................................................................. 64 2.1.5 Tissue stains and immunohistochemistry
Load more

Recommended publications
  • Two Locus Inheritance of Non-Syndromic Midline Craniosynostosis Via Rare SMAD6 and 4 Common BMP2 Alleles 5 6 Andrew T
    1 2 3 Two locus inheritance of non-syndromic midline craniosynostosis via rare SMAD6 and 4 common BMP2 alleles 5 6 Andrew T. Timberlake1-3, Jungmin Choi1,2, Samir Zaidi1,2, Qiongshi Lu4, Carol Nelson- 7 Williams1,2, Eric D. Brooks3, Kaya Bilguvar1,5, Irina Tikhonova5, Shrikant Mane1,5, Jenny F. 8 Yang3, Rajendra Sawh-Martinez3, Sarah Persing3, Elizabeth G. Zellner3, Erin Loring1,2,5, Carolyn 9 Chuang3, Amy Galm6, Peter W. Hashim3, Derek M. Steinbacher3, Michael L. DiLuna7, Charles 10 C. Duncan7, Kevin A. Pelphrey8, Hongyu Zhao4, John A. Persing3, Richard P. Lifton1,2,5,9 11 12 1Department of Genetics, Yale University School of Medicine, New Haven, CT, USA 13 2Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA 14 3Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA 15 4Department of Biostatistics, Yale University School of Medicine, New Haven, CT, USA 16 5Yale Center for Genome Analysis, New Haven, CT, USA 17 6Craniosynostosis and Positional Plagiocephaly Support, New York, NY, USA 18 7Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA 19 8Child Study Center, Yale University School of Medicine, New Haven, CT, USA 20 9The Rockefeller University, New York, NY, USA 21 22 ABSTRACT 23 Premature fusion of the cranial sutures (craniosynostosis), affecting 1 in 2,000 24 newborns, is treated surgically in infancy to prevent adverse neurologic outcomes. To 25 identify mutations contributing to common non-syndromic midline (sagittal and metopic) 26 craniosynostosis, we performed exome sequencing of 132 parent-offspring trios and 59 27 additional probands.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Essential Genes and Their Role in Autism Spectrum Disorder
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Essential Genes And Their Role In Autism Spectrum Disorder Xiao Ji University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, and the Genetics Commons Recommended Citation Ji, Xiao, "Essential Genes And Their Role In Autism Spectrum Disorder" (2017). Publicly Accessible Penn Dissertations. 2369. https://repository.upenn.edu/edissertations/2369 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2369 For more information, please contact [email protected]. Essential Genes And Their Role In Autism Spectrum Disorder Abstract Essential genes (EGs) play central roles in fundamental cellular processes and are required for the survival of an organism. EGs are enriched for human disease genes and are under strong purifying selection. This intolerance to deleterious mutations, commonly observed haploinsufficiency and the importance of EGs in pre- and postnatal development suggests a possible cumulative effect of deleterious variants in EGs on complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired social interaction, communication and repetitive behavior. More and more genetic evidence points to a polygenic model of ASD and it is estimated that hundreds of genes contribute to ASD. The central question addressed in this dissertation is whether genes with a strong effect on survival and fitness (i.e. EGs) play a specific oler in ASD risk. I compiled a comprehensive catalog of 3,915 mammalian EGs by combining human orthologs of lethal genes in knockout mice and genes responsible for cell-based essentiality.
    [Show full text]
  • Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.020206; this version posted April 2, 2020. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I. Krahn, Carrow Wells, David H. Drewry, Lenore K. Beitel, Thomas M. Durcan, Alison D. Axtman* ABSTRACT: Kinases are highly tractable drug targets that have reached unparalleled success in fields such as cancer but whose potential has not yet been realized in neuroscience. There are currently 55 approved small molecule kinase-targeting drugs, 48 of which have an anti-cancer indication. The intrinsic complexity linked to central nervous system (CNS) drug development and a lack of validated targets has hindered progress in developing kinase inhibitors for CNS disorders when compared to other therapeutic areas such as oncology. Identification and/or characterization of new kinases as potential drug targets for neurodegenerative diseases will create opportunities for development of CNS drugs in the future. The track record of kinase inhibitors in other disease indications supports the idea that with the best targets identified small molecule kinase modulators will become impactful therapeutics for neurodegenerative diseases. KEYWORDS: kinase, neurodegeneration,
    [Show full text]
  • NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development Via CDK Activation
    Published OnlineFirst April 1, 2015; DOI: 10.1158/0008-5472.CAN-13-3209 Cancer Therapeutics, Targets, and Chemical Biology Research NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation Takeshi Namiki1,2,3, Tomonori Yaguchi2, Kenta Nakamura2,4, Julio C. Valencia1, Sergio G. Coelho1, Lanlan Yin1, Masakazu Kawaguchi1, Wilfred D. Vieira1, Yasuhiko Kaneko5, Atsushi Tanemura6, Ichiro Katayama6, Hiroo Yokozeki3, Yutaka Kawakami2, and Vincent J. Hearing1 Abstract The AMPK-related kinase NUAK2 has been implicated in number of cells in S phase. NUAK2 silencing and inactivation of melanoma growth and survival outcomes, but its therapeutic the PI3K pathway efficiently controlled CDK2 expression, where- utility has yet to be confirmed. In this study, we show how as CDK2 inactivation specifically abrogated the growth of its genetic amplification in PTEN-deficient melanomas may NUAK2-amplified and PTEN-deficient melanoma cells. Immu- rationalize the use of CDK2 inhibitors as a therapeutic strategy. nohistochemical analyses confirmed an association of CDK2 Analysis of array-CGH data revealed that PTEN deficiency is expression with NUAK2 amplification and p-Akt expression in coupled tightly with genomic amplification encompassing the melanomas. Finally, pharmacologic inhibition of CDK2 was NUAK2 locus, a finding strengthened by immunohistochemical sufficient to suppress the growth of NUAK2-amplified and evidence that phospho-Akt overexpression was correlated with PTEN-deficient melanoma cells in vitro and in vivo. Overall, our NUAK2 expression in clinical specimens of acral melanoma. results show how CDK2 blockade may offer a promising therapy Functional studies in melanoma cells showed that inactivation for genetically defined melanomas, where NUAK2 is amplified of the PI3K pathway upregulated p21 expression and reduced the and PTEN is deleted.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • Management of Women with Premature Ovarian Insufficiency
    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
    [Show full text]
  • Biological Role of Conceptus Derived Factors During Early Pregnancy In
    Biological Role of Conceptus Derived Factors During Early Pregnancy in Ruminants A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY IN ANIMAL SCIENCES UNIVERSITY OF MISSOURI- COLUMBIA Division of Animal Science By KELSEY BROOKS Dr. Thomas Spencer, Dissertation Supervisor August 2016 The undersigned have examined the dissertation entitled, BIOLOGICAL ROLE OF CONCEPTUS DERIVED FACTORS DURING EARLY PREGNANCY IN RUMINANTS presented by Kelsey Brooks, a candidate for the degree of doctor of philosophy, and hereby certify that, in their opinion, it is worthy of acceptance. __________________________________ Chair, Dr. Thomas Spencer ___________________________________ Dr. Rodney Geisert ___________________________________ Dr. Randall Prather ___________________________________ Dr. Laura Schulz ACKNOWLEDGMENTS I would like to acknowledge all the students, faculty and staff at Washington State University and the University of Missouri for their help and support throughout my doctoral program. I am grateful for the opportunity to work with Dr. Thomas Spencer, and thank him for his input and guidance not only in planning experiments and completing projects but for helping me turn my love of science into a career in research. I would also like to acknowledge the members of my graduate committee at Washington State University for their help and input during the first 3 years of my studies. A special thanks to Dr. Jim Pru and Cindy Pru for providing unlimited entertainment, and the occasional missing reagent. Thank you to my committee members at the University of Missouri for adopting me late in my program and helping shape my future as an independent scientist. Thanks are also extended to members of the Prather lab and Wells lab for letting me in on the secrets of success using the CRISPR/Cas9 system.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development Via CDK Activation
    Published OnlineFirst April 1, 2015; DOI: 10.1158/0008-5472.CAN-13-3209 Cancer Therapeutics, Targets, and Chemical Biology Research NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation Takeshi Namiki1,2,3, Tomonori Yaguchi2, Kenta Nakamura2,4, Julio C. Valencia1, Sergio G. Coelho1, Lanlan Yin1, Masakazu Kawaguchi1, Wilfred D. Vieira1, Yasuhiko Kaneko5, Atsushi Tanemura6, Ichiro Katayama6, Hiroo Yokozeki3, Yutaka Kawakami2, and Vincent J. Hearing1 Abstract The AMPK-related kinase NUAK2 has been implicated in number of cells in S phase. NUAK2 silencing and inactivation of melanoma growth and survival outcomes, but its therapeutic the PI3K pathway efficiently controlled CDK2 expression, where- utility has yet to be confirmed. In this study, we show how as CDK2 inactivation specifically abrogated the growth of its genetic amplification in PTEN-deficient melanomas may NUAK2-amplified and PTEN-deficient melanoma cells. Immu- rationalize the use of CDK2 inhibitors as a therapeutic strategy. nohistochemical analyses confirmed an association of CDK2 Analysis of array-CGH data revealed that PTEN deficiency is expression with NUAK2 amplification and p-Akt expression in coupled tightly with genomic amplification encompassing the melanomas. Finally, pharmacologic inhibition of CDK2 was NUAK2 locus, a finding strengthened by immunohistochemical sufficient to suppress the growth of NUAK2-amplified and evidence that phospho-Akt overexpression was correlated with PTEN-deficient melanoma cells in vitro and in vivo. Overall, our NUAK2 expression in clinical specimens of acral melanoma. results show how CDK2 blockade may offer a promising therapy Functional studies in melanoma cells showed that inactivation for genetically defined melanomas, where NUAK2 is amplified of the PI3K pathway upregulated p21 expression and reduced the and PTEN is deleted.
    [Show full text]
  • Supplemental Tables
    Supplemental Tables 1 (Up in 1 (Up in Log2 AD80) / 2 Log2 1 (Up in Log2 AD80) / 2 Fold (Low in Fold AD80) / 2 Fold Gene (Low in AD30) change Gene AD30) change Gene (Low in AD30) change G6PC 1 8.262795 SYT8 1 3.826244 SPATA9 1 3.10268 ADH1B 1 7.508264 ADH4 1 3.800391 SPTSSB 1 3.093815 RNU1-70P 1 6.596403 WNT8B 1 3.799741 CYP26A1 1 3.093672 CYP7A1 1 6.56167 TNFSF10 1 3.795007 ACR 1 3.092358 ADH1A 1 6.358759 HMGCS2 1 3.791218 DUOX2 1 3.090622 SLC2A2 1 6.05681 GNAT1 1 3.737262 SPTLC3 1 3.086353 TNFRSF14- AS1 1 6.055208 CFHR4 1 3.732386 FER1L5 1 3.081569 IGFALS 1 5.825777 BSND 1 3.718276 RASA4CP 1 3.080765 LINC00957 1 5.727226 TSPOAP1 1 3.709555 DOC2GP 1 3.057021 TTBK1 1 5.724558 SLC22A7 1 3.698323 VAT1L 1 3.051293 CYP3A43 1 5.674953 AOC4P 1 3.68655 FMO3 1 3.031314 HNF4A- UGT1A9 1 5.643359 AS1 1 3.679788 SFRP5 1 3.016623 APOL3 1 5.448612 FHAD1 1 3.665007 RFX6 1 3.015833 - VCAM1 1 5.442271 ADAMTS10 1 3.61034 SLC5A8 2 3.015901 BFSP2 1 5.396028 NUDT13 1 3.562774 LFNG 2 -3.01667 C22orf31 1 5.349548 FYTTD1P1 1 3.544783 CXCR4 2 -3.0544 FOXN1 1 5.19046 CHAD 1 3.534052 GPR3 2 -3.099 - A2MP1 1 5.186347 IRF5 1 3.517716 PA2G4P6 2 3.103813 - UROC1 1 5.056845 GSTA7P 1 3.504839 PRDM8 2 3.140796 - XAF1 1 5.053767 CXCL10 1 3.486513 DGKG 2 3.261431 - ADAMTS14 1 5.049252 SERPINA2 1 3.481204 BCAN 2 3.389266 - UGT1A8 1 5.048674 WDR93 1 3.475799 MMP10 2 3.411248 - TTLL11-IT1 1 4.965854 MAP6 1 3.465613 MYBPC3 2 3.492397 HRC 1 4.853162 MOV10L1 1 3.457172 MUC12 2 -3.55192 - MOGAT2 1 4.797347 HP 1 3.456436 FGF18 2 3.551928 - SEPT7P9 1 4.735573 MT1B 1 3.43852 MYO1G
    [Show full text]
  • Supplemental File
    SUPPLEMENTARY MATERIALS AND METHODS ### reorder as minimun to maximum relative induction. allks2=cbind(allks,apply(allks,1,sum)) For the different analyses, the macros are as following: allks3=allks2[order(allks2[,length(colnames(allks2))]),] allks5=allks3[,-length(colnames(allks2))] -Heatmap and correlation analyses # check allks5 source("http://bioconductor.org/biocLite.R") biocLite() -Heatmap install.packages("gplots") library("gplots") #Set a color scale "zero centered" #Set Graph title (do one by one) breaks=c(seq(-(max(allks5)), max(allks5) , by = 0.05)) titre = "allkinases SASP " mycol <- colorpanel(n=length(breaks)- titre = "allkinases SASP + p16" 1,low="green",mid="black",high="red") titre = "allkinases SASP + p16 + NFkB" #Load Normalized RT-QPCR table (do one by one) # Heatmap, "symkey = T" allks<-read.table("allkS.txt", header = TRUE, sep = "\t", dec = ",", fill = TRUE, , row.names=1 ) dev.off() allks<-read.table("allkSp16.txt", header = TRUE, sep = heatmap.2(allks5, scale = "none", col = mycol, "\t", dec = ",", fill = TRUE, , row.names=1 ) breaks=breaks, symkey = F, allks<-read.table("allkSp16NFkB.txt", header = TRUE, trace = 'none', cexRow=0.8, cexCol = 1.6, srtCol sep = "\t", dec = ",", fill = TRUE, , row.names=1 ) = 0, keysize = 1.3, -Log2 relative fold changes induction calculation key.title = "", margins = c(8, 10), # matrix of minimun values main = paste("relative FC"," ", titre), min=apply(allks, 2, min ) Rowv=F mat<-matrix(min, length(row.names(allks)),length(colnames(allks)), -corrgram byrow=TRUE) # check mat install.packages("corrgram")
    [Show full text]